摘要
目的 对贝利尤单抗治疗儿童系统性红斑狼疮(cSLE)的疗效、联合用药、安全性等方面进行总结综述,以期为贝利尤单抗在cSLE患儿中应用提供参考。方法 对2019年1月至2024年7月Pub Med、Web of Science、Cochrane图书馆、Embase、中国知网、维普网、万方数据知识服务平台中关于贝利尤单抗治疗cSLE的临床研究文献进行全面检索,并对纳入文献进行系统性的质量评估与综合分析。结果 贝利尤单抗可提高cSLE的临床缓解率、降低疾病活动度及改善免疫学指标,同时能有效减轻炎症和靶器官功能损伤,对有严重并发症的患儿亦有显著疗效,联合用药时可明显改善患儿的临床症状以及降低激素、免疫抑制剂的用药剂量,具有良好耐受性及较低不良反应。结论 贝利尤单抗在cSLE患儿中具有良好的疗效和安全性,是治疗cSLE的一种潜在有效药物。
Objective To review the efficacy,combination therapy,and safety of belimumab in treating childhood-onset systemic lupus erythematosus(cSLE)to provide a reference for applying belimumab in cSLE patients.Methods A thorough literature search was conducted across PubMed,Web of Science,Cochrane Library,Embase,CNKI,Weipu,and Wanfang databases for clinical trials on belimumab treatment for cSLE from January 2019 to July 2024.The included studies underwent systematic quality assessment and comprehensive analysis.Results Belimumab significantly improved the clinical remission rate,reduced disease activity,and enhanced immunological markers in cSLE patients.It effectively alleviated inflammation and organ function damage,showing notable benefits for those with severe complications.Combined with corticosteroids and immunosuppressants,it could markedly improve clinical symptoms and reduce the dosage of drugs.Meanwhile,belimumab showed good tolerability and acceptable side effects.Conclusion Belimumab exhibits considerable effectiveness and a favorable safety in cSLE patients.So it is a potential effective drug for the treatment of cSLE.
作者
王文博
狄亚珍
Wang Wen-bo;Di Ya-zhen(Health Science Center,Ningbo University,Ningbo 315211,China;Department of Paediatric Rheumatology and Immunology,Affiliated Women's and Children's Hospital of Ningbo University,Ningbo 315012,China)
出处
《中国药物应用与监测》
CAS
2024年第5期679-684,共6页
Chinese Journal of Drug Application and Monitoring
